Table 2.

Frequencies, crude and adjusted odds ratios (OR) for polymorphisms in risk of esophageal adenocarcinoma cases and controls

	Case (%)	Control (%)	p-valuea	Crude OR (95% CI)	Adjusted ORb (95% CI)
XPD Lys751Gln
Lys/Lys	104 (33)	193 (43)		1	1
Lys/Gln	159 (51)	208 (46)		1.40 (1.0–1.9)	1.45 (1.1–2.0)
Gln/Gln	49 (16)	52 (11)	0.02	1.75 (1.1–2.8)	1.68 (1.0–2.7)
Gln/−				1.49 (1.1–2.0)	1.50 (1.1–2.0)
XPD Asp312Asn
Asp/Asp	117 (38)	199 (44)		1	1
Asp/Asn	150 (48)	206 (45)		1.24 (0.9–1.7)	1.27 (0.9–1.7)
Asn/Asn	43 (14)	49 (11)	0.18	1.49 (0.9–2.4)	1.46 (0.9–2.4)
Asn/−				1.29 (0.9–1.7)	1.30 (0.9–1.8)
ERCC1 8092C/A
C/C	157 (50)	259 (57)		1	1
A/C	127 (41)	167 (37)		1.26 (0.9–1.7)	1.38 (1.0–1.9)
A/A	28 (9)	28 (6)	0.12	1.65 (0.9–2.9)	1.81 (1.0–3.2)
A/−				1.31 (1.0–1.8)	1.44 (1.1–1.9)
ERCC1 118C/T
C/C	59 (19)	73 (16)		1	1
T/C	147 (47)	197 (43)		1.29 (0.9–1.8)	1.39 (1.0–1.9)
T/T	106 (34)	183 (40)	0.18	1.40 (0.9–2.1)	1.52 (1.0–2.3)
T/−				1.32 (1.0–1.8)	1.42 (1.0–1.9)
XRCC1 Arg399Gln
Arg/Arg	136 (44)	216 (48)		1	1
Arg/Gln	133 (43)	182 (40)		1.16 (0.9–1.6)	1.15 (0.8–1.6)
Gln/Gln	42 (14)	54 (12)	0.52	1.24 (0.8–2.0)	1.32 (0.8–2.1)
Gln/−				1.18 (0.9–1.6)	1.19 (0.9–1.6)
APE1 Asp148Glu
Asp/Asp	75 (24)	123 (27)		1	1
Asp/Glu	162 (52)	228 (50)		1.06 (0.8–1.5)	1.08 (0.8–1.5)
Glu/Glu	74 (24)	103 (23)	0.65	0.97 (0.5–1.8)	0.87 (0.4–1.7)
Glu/−				1.05 (0.8–1.4)	1.05 (0.8–1.4)
hOGG1 Ser326Cys
Ser/Ser	198 (64)	294 (65)		1	1
Ser/Cys	95 (31)	133 (29)		1.17 (0.8–1.7)	1.25 (0.9–1.8)
Cys/Cys	17 (5)	26 (6)	0.93	1.18 (0.8–1.8)	1.20 (0.8–1.8)
Cys/−				1.17 (0.8–1.6)	1.23 (0.9–1.7)

^aPearson’s Chi square test

^bAdjusted for age, sex, smoking status, and adult BMI